The REMox TB trial, one of the largest clinical studies in the field, assessed whether replacement of INH or EMB in the standard regimen RIF/INH/EMB/PZA by the DNA-gyrase inhibitor MFX could shorten treatment time to 4 months. Here, TOP2A is linked to tuberculosis.